Zai Lab Limited (NASDAQ:ZLAB) Position Raised by Allianz Asset Management GmbH

Allianz Asset Management GmbH boosted its stake in Zai Lab Limited (NASDAQ:ZLAB - Free Report) by 188.6% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,505,866 shares of the company's stock after acquiring an additional 984,041 shares during the period. Allianz Asset Management GmbH owned 1.38% of Zai Lab worth $39,442,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ZLAB. Janus Henderson Group PLC boosted its holdings in Zai Lab by 34.2% during the third quarter. Janus Henderson Group PLC now owns 8,760,074 shares of the company's stock worth $211,488,000 after purchasing an additional 2,232,507 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Zai Lab by 18.4% in the third quarter. Wellington Management Group LLP now owns 8,436,606 shares of the company's stock worth $203,660,000 after buying an additional 1,312,115 shares in the last quarter. Bamco Inc. NY boosted its holdings in Zai Lab by 6.4% in the 3rd quarter. Bamco Inc. NY now owns 1,906,520 shares of the company's stock valued at $46,023,000 after purchasing an additional 113,869 shares during the period. Principal Financial Group Inc. bought a new stake in Zai Lab during the fourth quarter valued at $46,172,000. Finally, Connor Clark & Lunn Investment Management Ltd. grew its holdings in shares of Zai Lab by 26.2% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 604,153 shares of the company's stock worth $14,584,000 after purchasing an additional 125,532 shares in the last quarter. 41.65% of the stock is currently owned by institutional investors and hedge funds.

Remove Ads

Insider Activity at Zai Lab

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the firm's stock in a transaction dated Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total transaction of $199,281.24. Following the transaction, the insider now owns 33,834 shares of the company's stock, valued at approximately $889,157.52. This trade represents a 18.31 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 13.88% of the stock is owned by company insiders.

Zai Lab Stock Performance

Shares of ZLAB stock traded down $0.69 during trading hours on Thursday, reaching $34.38. The company had a trading volume of 1,593,393 shares, compared to its average volume of 856,289. The business has a fifty day moving average price of $27.35 and a 200-day moving average price of $25.63. The firm has a market cap of $3.76 billion, a PE ratio of -12.41 and a beta of 1.02. Zai Lab Limited has a one year low of $13.48 and a one year high of $36.60.

Zai Lab (NASDAQ:ZLAB - Get Free Report) last released its earnings results on Thursday, February 27th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.15). Zai Lab had a negative return on equity of 36.97% and a negative net margin of 76.14%. Equities research analysts forecast that Zai Lab Limited will post -2.58 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Cantor Fitzgerald upgraded shares of Zai Lab to a "strong-buy" rating in a research report on Wednesday, February 5th.

Zai Lab Company Profile

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.